Introduction: Psoriasis is a chronic multi-systemic inflammatory skin disease that presents with erythema, thickness, and scaling of the skin. Genetic and environmental factors are associated with its etiology. Recently systemic immune inflammatory index, has been proposed as a biomarker for prognosis and severity prediction. Although it has been studied in psoriasis in general, no study exists for its association with the individual types of psoriasis. This study thus aimed to determine its association with clinical characteristics of psoriasis subtypes. Materials and Methods: Data were retrospectively retrieved from the hospital electronic medical database from January 2020 to August 2022. Only patients with CBC results were included. Clinical data retrieved were: Patients’ age, gender, type of psoriasis diagnosed, body mass index, duration of the disease, family history of psoriasis, history of smoking, diabetes, and hypertension records. Laboratory data retrieved were: Complete blood count (CBC), C-reactive protein, Immunoglobulin E (IgE), Total cholesterol, Triglycerides and Low-density lipoprotein cholesterol. Data were analyzed in SPSS and GraphPad prism. Results: The study enrolled 85 patients with psoriasis; 56.47% males, and 43.53% females. 7.6% had psoriasis for less than 10 years, while 42.4% had the disease for more than 10 years. Psoriasis vulgaris was the most common diagnosis, 41.2%, followed by p. pustular, 30.6% and then p. erythroderma 28.2%. Mean age ± SD of the p. vulgaris, p. pustular and p. erythroderma patients were 47.3 ± 15.3; 45.3 ± 14.6, and 57.1 ± 11.7 respectively. SII was significantly higher in p. pustular than the rest, (p < 0.0001). SII was significantly associated with hypertension p. pustular patients. C-reactive protein was significantly upregulated in both psoriasis pustular and erythroderma but not vulgaris (all p < 0.001), while leukocytosis was observed in psoriasis pustular. Conclusion: In summary, systemic immune inflammatory index (SII) was significantly higher in psoriasis pustular than other subtypes of psoriasis, and had an association with hypertension in psoriasis pustular patients. These findings suggest a possible association between SII and psoriasis pustular that should be investigated in an independent study.
References
[1]
Bahar, A., Dincer, K. and Sezer, S. (2022) Systemic Immune Inflammation Index as a Reliable Disease Activity Marker in Psoriatic Arthritis. Journal of the College of Physicians and Surgeons Pakistan, 32, 773-778. https://doi.org/10.29271/jcpsp.2022.06.773
[2]
Atakan, N., Yazici, A.C., Özarmaʇan, G., et al. (2016) TUR-PSO: A Cross-Sectional, Study Investigating Quality of Life and Treatment Status of Psoriasis Patients in Turkey. Journal of Dermatology, 43, 298-304. https://doi.org/10.1111/1346-8138.13081
[3]
Goto, H., Nakatani, E., Yagi, H., et al. (2020) Late-Onset Development of Psoriasis in Japan: A Population-Based Cohort Study. JAAD International, 2, 51-61. https://doi.org/10.1016/j.jdin.2020.10.011
[4]
Matthew, M. and Pranev, S. (2009) Clinical Spectrum and Severity of Psoriasis. Current Problems in Dermatology, 38, 1-20. https://doi.org/10.1159/000232301
[5]
Pan, R. and Zhang, J. (2014) Epidemiology and Treatment of Psoriasis: A Chinese Perspective. Psoriasis: Targets and Therapy, 4, 37-47. https://www.dovepress.com/epidemiology-and-treatment-of-psoriasis-a-chinese-perspective-peer-reviewed-fulltext-article-PTT https://doi.org/10.2147/PTT.S51717
Deng, Y., Chang, C. and Lu, Q. (2016) The Inflammatory Response in Psoriasis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 50, 377-389. https://doi.org/10.1007/s12016-016-8535-x
[9]
Yorulmaz, A., Hayran, Y., Akpinar, U. and Yalcin, B. (2020) Systemic Immune-Inflammation Index (SII) Predicts Increased Severity in Psoriasis and Psoriatic Arthritis. Current Health Sciences Journal, 46, 352-357.
[10]
Chung, W.S. and Lin, C.L. (2017) Increased Risks of Venous Thromboembolism in Patients with Psoriasis: A Nationwide Cohort Study. Thrombosis and Haemostasis, 117, 1637-1643. https://doi.org/10.1160/TH17-01-0039
[11]
Rendon, A. and Schäkel, K. (2019) Psoriasis Pathogenesis and Treatment. International Journal of Molecular Sciences, 20, 1-28. https://doi.org/10.3390/ijms20061475
[12]
Sii, H.S., Wang, J. and Ruxton, T. (2001) Novel Risk Assessment Techniques for Maritime Safety Management System. International Journal of Quality and Reliability Management, 18, 982-999. https://doi.org/10.1108/02656710110407145
[13]
Kapoor, B., Gulati, M., Rani, P. and Gupta, R. (2022) Psoriasis: Interplay between Dysbiosis and Host Immune System. Autoimmunity Reviews, 21, Article ID: 103169. https://www.sciencedirect.com/science/article/pii/S1568997222001392 https://doi.org/10.1016/j.autrev.2022.103169
[14]
Chong, B.F. and Wong, H.K. (2007) Immunobiologics in the Treatment of Psoriasis. Clinical Immunology, 123, 129-138. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309380 https://doi.org/10.1016/j.clim.2007.01.006
[15]
Ogawa, E., Sato, Y., Minagawa, A. and Okuyama, R. (2018) Pathogenesis of Psoriasis and Development of Treatment. Journal of Dermatology, 45, 264-272. https://doi.org/10.1111/1346-8138.14139
[16]
Mak, R.K.H., Hundhausen, C. and Nestle, F.O. (2009) Progress in Understanding the Immunopathogenesis of Psoriasis. Actas Dermo-Sifiliográficas, 100, 2-13. https://doi.org/10.1016/S0001-7310(09)73372-1
[17]
Lowes, M.A., Suárez-Fariñas, M. and Krueger, J.G. (2014) Immunology of Psoriasis. Annual Review of Immunology, 32, 227-255. https://doi.org/10.1146/annurev-immunol-032713-120225
[18]
Grän, F., Kerstan, A., Serfling, E., et al. (2020) Current Developments in the Immunology of Psoriasis. Yale Journal of Biology and Medicine, 93, 97-110.
[19]
Ding, X., Wang, T., Shen, Y., et al. (2012) Prevalence of Psoriasis in China: A Population-Based Study in Six Cities. European Journal of Dermatology, 22, 663-667. https://doi.org/10.1684/ejd.2012.1802
[20]
Liu, C.H., Ji, M.R., Fang, X., et al. (1988) Peripheral Leukocytes in Psoriasis. International Journal of Dermatology, 27, 638-641. https://doi.org/10.1111/j.1365-4362.1988.tb02422.x
[21]
Papa, C.A. and Miller, O.F. (1998) Pustular Psoriasiform Eruption with Leukocytosis Associated with Terbinafine. Journal of the American Academy of Dermatology, 39, 115-117. https://www.jaad.org/article/S0190-9622(98)70411-6/fulltext https://doi.org/10.1016/S0190-9622(98)70411-6
[22]
Arriaza, O., Garcia, B., Gonzalez, A.M., et al. (2022) 34193 Psoriasiform Eruption after Treatment with Pembrolizumab. Journal of the American Academy of Dermatology, 87, AB196. https://www.jaad.org/article/S0190-9622(22)01865-5/fulltext https://doi.org/10.1016/j.jaad.2022.06.817
[23]
Bu, J., Ding, R., Zhou, L., et al. (2022) Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Frontiers in Immunology, 13, Article ID: 880201. https://www.frontiersin.org/articles/10.3389/fimmu.2022.880201 https://doi.org/10.3389/fimmu.2022.880201
[24]
Sajja, A., Abdelrahman, K.M., Reddy, A.S., et al. (2020) Chronic Inflammation in Psoriasis Promotes Visceral Adiposity Associated with Noncalcified Coronary Burden over Time. JCI Insight, 5, e142534. https://insight.jci.org/articles/view/142534 https://doi.org/10.1172/jci.insight.142534
[25]
Sokolova, M.V., Simon, D., Nas, K., et al. (2020) A Set of Serum Markers Detecting Systemic Inflammation in Psoriatic Skin, Entheseal, and Joint Disease in the Absence of C-Reactive Protein and Its Link to Clinical Disease Manifestations. Arthritis Research & Therapy, 22, Article No. 26. https://doi.org/10.1186/s13075-020-2111-8
[26]
Ye, Z., Hu, T., Wang, J., et al. (2022) Systemic Immune-Inflammation Index as a Potential Biomarker of Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article ID: 933913. https://www.frontiersin.org/articles/10.3389/fcvm.2022.933913 https://doi.org/10.3389/fcvm.2022.933913
[27]
Tang, Y., Zeng, X., Feng, Y., et al. (2021) Association of Systemic Immune-Inflammation Index with Short-Term Mortality of Congestive Heart Failure: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 8, Article ID: 753133. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632819 https://doi.org/10.3389/fcvm.2021.753133
